NOTE: You must login to your Alliance account to access the articles and resources below. Some content may only be accessible to Alliance members.
Recording: Specialty Drugs Trends and Issues Affecting Self-Funded Plans
The Phia Group's legal team discusses the latest trends and issues relating to specialty drugs including plan design, international sourcing, copay programs, and more.
Article: Civica Rx: Not-for profit generic drug firm
The not-for-profit generic drug firm that aims to prevent drug shortages and cut prices for patients now has a name and a boss. The effort will be called Civica Rx, and it will be run by chief executive Martin VanTrieste, the former chief quality officer for Amgen.
Brochure: The Complete Prescription Management Platform
At RxRevu, we believe in improving the value of healthcare through informed, cost-effective, consistent prescribing decisions. We deliver real-time, patient-specific cost information, electronic prior authorization, and therapeutic alternatives at the point of care within our next generation Prescription Decision Support platform. By doing so, we enable shared decisions between providers and patients, help patients get the right medication the first time, and remove friction from the point of care to fulfillment.
Presentation: Increasing Value through Pharmacy
Community Health Options and Rx Savings Solutions share the mechanics of their partnership and improved member outcomes and plan results. Transparency tools, savings identification, and formulary management all combine for greater savings for member and plan alike while contributing to increased access and adherence. Presented at the Fall Leadership Forum in Boston, October 10-12, 2018.
Presentation: Specialty Drug Management
Health Alliance Plan discusses specialty drug management at the Pharmacy networking meeting in Dallas, May 2018.
Presentation: IPD Analytics-Solutions for Payors
IPD Analytics presents solutions to help payors manage costs and complexity through payor insights, financial forecasting and coding and pricing information at our Pharmacy networking meeting held in Dallas, May 2018.
Presentation: Federal managed care pharmacy policy issues
AMCP discusses updates from Washington and the states legislative and regulatory perspectives on managed care pharmacy at the Pharmacy networking meeting in Dallas, May 2018.
Presentation: CMS Part D Final 2018 Rules
BluePeak Advisors discuss the CMS Part D Final Rule and the 2019 Medicare Call Letter at the Pharmacy networking meeting in Dallas, May 2018. The presentation includes what you need to know about the CMS Part D 2018 Final Rule as well as the biggest changes in the 2019 Medicare Call Letter and what may come next.
Presentation: Prescription Drug Costs: State Policy Overview
National Academy for State Health Policy presents current and emerging issues with State Legislation and issues with drug pricing and importation at our Pharmacy networking meeting in Dallas, May 2018.
Presentation: Using Big Data for Patient Engagement from RxEOB
RxEOB presents an educational session around application of big data and analytics for more effective patient engagement at our Pharmacy networking meeting in Dallas, May 2018.
Presentation: Opioid Management Health Alliance Plan
Health Alliance Plan presents on strategies and initiatives to address more effective opioid management at our Pharmacy networking meeting in Dallas, May 2018.
Presentation: Strategies for MA STAR Ratings Success
Scott & White Health Plan and Presbyterian Health Plan provide effective strategies to help optimize plan success withÂ Medicare Advantage STAR ratings at the Pharmacy networking meeting in Dallas, May 2018.
2018 and Beyond: Pharmacy Outlook and Turning Points
IQVIA presents the outlook for pharmacy 2018 and beyond.
Biotech and Spec Pharma: A deeper look into copay accumulators - mechanisms, near term impact, pharma counter strategies
This Bernstein & Co. article explores the implications of copay accumlulators for biotech and specialty pharmaceuticals.
Global Pharmaceuticals: 1Q18 EPS preview - model changes & updated perspectives
Bernstein & Company announce highlights and upcoming Q1 EPS results for their ten covered US/EU pharmaceutical companies.